Zorvolex

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Zorvolex

What is Zorvolex

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a type of non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It works by blocking enzymes that cause the production of substances in the body that cause inflammation and pain. Diclofenac is the product of a rational drug design and is often prescribed as a first-line therapy for various types of pain and inflammation. It is often used in combination with a medication called misoprostol to prevent stomach ulcers caused by NSAIDs. Diclofenac was first approved by the FDA in 1988 under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Zorvolex Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Zorvolex Affects Patients

Diclofenac is an anti-inflammatory drug used to reduce pain and fever. Unfortunately, it can also reduce the amount of mucus in the stomach that helps protect it from ulcers.

How Zorvolex works in the body

Diclofenac works by blocking enzymes responsible for creating molecules that cause pain and inflammation. It also affects how neurons respond to pain signals, making them less sensitive. Diclofenac also reduces swelling by stopping white blood cells from flowing to sites of inflammation. It blocks molecules that cause vasodilation and increase nutrient flow, too. In addition, it can reduce the body's overall immune response and stop certain molecules from crossing the blood-brain barrier, thus reducing fever.

When to interrupt dosage

The proposed dosage of Zorvolex is contingent upon the diagnosed condition, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The quantity of dosage alters, per the administration modality (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) identified in the table below.

Condition

Dosage

Administration

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Muscle Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Fever

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Surgery, Dental

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Osteoarthritis of the Knee

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Sprains and Strains

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Wounds, Nonpenetrating

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Musculoskeletal System

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Warnings

Zorvolex Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Zorvolex.

Common Zorvolex Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Zorvolex Toxicity & Overdose Risk

Symptoms of Voltaren overdose may include tiredness, drowsiness, nausea, vomiting, stomach pain, and bleeding from the digestive tract. High blood pressure, kidney failure, shallow breathing, or coma can occur in rare cases. If the overdose happened within the last 4 hours, medical professionals may induce vomiting and administer activated charcoal.

image of a doctor in a lab doing drug, clinical research

Zorvolex Novel Uses: Which Conditions Have a Clinical Trial Featuring Zorvolex?

491 active clinical trials are currently underway to assess the potential of Zorvolex in ameliorating Inflammation, Argon Laser Trabeculoplasty and Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

59 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3

Osteoarthritis of the Knee

78 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

118 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

20 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

2 Actively Recruiting

Phase 4, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

5 Actively Recruiting

Not Applicable

Pain

2 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Zorvolex Reviews: What are patients saying about Zorvolex?

5

Patient Review

3/30/2016

Zorvolex for Pain

Even with my insurance and the savings card, Zorvolex is going to cost $193.00 for a 30 day supply--which is way too much. 800 mg of Iburophen works just as well for me and it's a lot cheaper.

5

Patient Review

9/9/2015

Zorvolex for Joint Damage causing Pain and Loss of Function

Before taking this medication, I could hardly get out of bed. Walking was a real challenge. But this drug has helped me immensely and I am now able to live a relatively normal life again.

5

Patient Review

10/14/2016

Zorvolex for Pain

Though it does require a bit of budgeting for the copay, this treatment has been well worth it for me. It's helped with mysciatic pain, spinal stenosis, and osteoarthritis in my hands. I can definitely tell when I miss a dose.

5

Patient Review

6/15/2016

Zorvolex for Joint Damage causing Pain and Loss of Function

I unfortunately got microscopic colitis after taking this medication. The diarrhea that resulted was truly awful. I had to take a steroid to get it under control, and my doctor says I'll have it for the rest of my life.

5

Patient Review

8/11/2017

Zorvolex for Inflammation of the Sac Surrounding the Joint - Bursitis

I found an old bottle of Zorvolex in my drawer, and even though it had expired by a full year, I decided to give it a try because the online reviews said it would help with inflammation. I'm so glad I took that chance! The pill worked amazingly, reducing the swelling and pain almost immediately. It was such a relief that I went back to my doctor and asked for more.

5

Patient Review

10/9/2017

Zorvolex for Joint Damage causing Pain and Loss of Function

Zorvolex has been an incredible help for my aching knees and back. I was struggling to even walk before taking this medication, but now I feel like I have new joints!

5

Patient Review

7/31/2015

Zorvolex for Joint Damage causing Pain and Loss of Function

Zorvolex completely alleviated the inflammation and pain I experience with Lupus and Sjogrens. No other medication has given me such relief, and without any side effects!

5

Patient Review

5/8/2015

Zorvolex for Joint Damage causing Pain and Loss of Function

This treatment has been effective in helping me to forget about my back issues and the pain that comes with it.

4.7

Patient Review

3/13/2016

Zorvolex for Inflammation of the Tendon

I was given samples of this medication from my doctor for inflammation and pain. I took it for less than two weeks, during which time I gained over 10 pounds. Not only did it not help with my pain, but it also caused me to gain a significant amount of weight.

4.7

Patient Review

4/2/2015

Zorvolex for Gout

4.3

Patient Review

7/10/2016

Zorvolex for Rheumatoid Arthritis

I was given this medication two years ago and it's been really effective at managing my pain without requiring me to take a lot of medication.

2.7

Patient Review

3/16/2016

Zorvolex for Pain

This drug helped me manage the pain of Plantar fasciitis for a while, which was greatly appreciated. However, after some time the pain subsided on its own and I no longer needed to take this medication.

2.3

Patient Review

11/12/2016

Zorvolex for Pain

This medication didn't do much to help with my pain. I'm not impressed and would like to try something else.

2.3

Patient Review

5/19/2015

Zorvolex for Pain

I was pleasantly surprised by how quickly this medication took effect. I haven't needed to use my opiate prescription today, which is a huge relief.

2

Patient Review

5/1/2016

Zorvolex for Acute Pain

Within a few days, this treatment helped lessen the pain of plantar fasciitis. I only use it now when absolutely necessary.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zorvolex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why was Zorvolex discontinued?

"ZORVOLEX is not recommended for use in patients undergoing CABG surgery due to the increased risk of serious gastrointestinal adverse events associated with NSAIDs. These events can include bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal."

Answered by AI

How much Zorvolex should I take?

"For mild to moderate acute pain, the dosage is 18 mg or 35 mg orally three times daily. For osteoarthritis pain, the dosage is 35 mg orally three times daily."

Answered by AI

What is the difference between Zorvolex and diclofenac?

"ZORVOLEX is available in lower dosage strengths (18-mg and 35-mg capsules) compared with other formulations of diclofenac which contain the sodium or potassium salt of diclofenac (Figure 2)."

Answered by AI

What is the drug Zorvolex used for?

"It is used to relieve pain from various conditions such as muscle aches, backaches, dental pain, menstrual cramps, and sports injuries. By reducing symptoms such as pain, swelling, and stiffness, it allows patients to return to their normal daily activities."

Answered by AI

Clinical Trials for Zorvolex

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+
All Sexes
Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting
Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Have you considered Zorvolex clinical trials?

We made a collection of clinical trials featuring Zorvolex, we think they might fit your search criteria.
Go to Trials
Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Image of Resilient Roots: Functional Medicine in Charlottesville, United States.

Ketogenic and Carnivore Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

18 - 64
All Sexes
Charlottesville, VA

This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative colitis and Crohn's disease\] (IBD) or rheumatoid arthritis (RA). Participants will be randomized into one of three groups: 1) Ketogenic Diet, 2) Carnivore (Lion) Diet or 3) Wait-List Control. Participants randomized to a dietary group (ketogenic diet or carnivore diet) will be provided guidance on their specific dietary therapy and answer questions about their symptoms and quality of life at different intervals over a 24 week period. Participants will also complete laboratory testing at different intervals to assess for changes in nutritional status, cardiometabolic health and markers of immune activation and inflammation. Participants initially placed on the wait-list group will be asked similar questions about their symptoms and quality of life and complete the same laboratory testing as participants in a dietary group. Participants on the wait list will then be compared to participants following a specific dietary pattern to assess for any differences between the 2 groups. After 12 weeks, participants on the wait list will be randomized to a dietary group (ketogenic diet or carnivore diet) and followed in a similar fashion for an additional 12 week period.

Recruiting
Has No Placebo

Resilient Roots: Functional Medicine

Robert D Abbott, MD

Have you considered Zorvolex clinical trials?

We made a collection of clinical trials featuring Zorvolex, we think they might fit your search criteria.
Go to Trials
Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Image of Marquette University in Milwaukee, United States.

Exercise for Pain

35 - 65
All Sexes
Milwaukee, WI

The goal of this clinical trial is to determine how male and female former athletes experience pain and respond to moderate-intensity exercise (strength versus aerobic) compared with both current master's athletes and nonathletes. The main questions this study aims to address are: 1. How do former athletes, master's athletes, and nonathletes experience pain? 2. How do different types of moderate-intensity exercise (strength versus aerobic exercise) influence pain in former athletes, master's athletes, and nonathletes? Participants will complete 3 different testing sessions: 1. Baseline testing including assessments of strength, cardiorespiratory fitness, and pain; 2. Strength exercise: pain assessments will occur before and after moderate-intensity strength training exercise; 3. Aerobic exercise: pain assessments will occur before and after moderate-intensity aerobic exercise. There will be a washout period of approximately one week or greater between each of the three different testing sessions. The order of conditions (strength versus aerobic exercise) will be randomized (crossover randomized trial design).

Recruiting
Has No Placebo

Marquette University

Jacob J Capin, DPT, PhD

Have you considered Zorvolex clinical trials?

We made a collection of clinical trials featuring Zorvolex, we think they might fit your search criteria.
Go to Trials